CG Results Healthcare has advised Datapharm on its investment from CGE Partners

  • Service: M&A
  • Sector: Healthcare, Technology
  • Sub Sector: HCIT
  • Engagement Type: Sell Side
Feb 2022
has received investment from

LONDON, 28th February 2022 – CGE Partners (“CGE”) is pleased to announce its investment in Datapharm, a leading provider of regulatory-driven medicines information and software solutions to the pharmaceutical industry. Datapharm’s core platform, the electronic medicines compendium (“emc”), is the UK’s leading source of trusted medicines information used by pharmaceutical companies, healthcare professionals and patients.

Datapharm lies at the core of the UK medicines information ecosystem, benefitting from 45 years of industry expertise and longstanding trusted relationships with customers. The business supports pharmaceutical companies in maintaining regulatory compliance and its software solutions are trusted by over 300 of the world’s top global life sciences companies. CGE is partnering with Datapharm’s management team to accelerate new product development, international expansion and strategic acquisitions.

Simon Abrams, CEO of Datapharm, commented: “We are excited to welcome CGE as our investment partner to achieve our vision of improving the accessibility and excellence of medicines information in the pharmaceutical industry. With CGE’s support, Datapharm will continue to expand its suite of best-in-class software solutions to our customers whilst maintaining its reputation for independence and trust.”

CGE Partners commented: “We are delighted to be partnering with Simon and the management team at Datapharm. Datapharm’s mission-critical solutions and commitment to patient safety and regulatory compliance strongly align with our focus on partnering with purposeful businesses that deliver a positive impact.”
Datapharm marks the sixth investment from CGE’s first fund.

>>>>> Read the press release here

CG Results expertly ran an outstanding process to achieve a terrific outcome for all stakeholders. The entire team were an absolute pleasure to work with - helpful, incredibly hard working and responsive. We even had some fun along the way. I have no hesitation in giving a wholehearted recommendation to anyone in health/health tech sectors considering a transaction.

Simon Abrams

CEO, Datapharm

Sector Related Deals